June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Corneal Epithelium-derived Thrombospondin-1 Regulates Dendritic Cell Maturation in Dry Eye Disease
Author Affiliations & Notes
  • William Foulsham
    Schepens Eye Research Institute, Boston, Massachusetts, United States
  • xuhua tan
    Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China
    Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Yihe Chen
    Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Afsaneh Amouzegar
    Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Yizhi liu
    Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China
  • Sunil Chauhan
    Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Reza Dana
    Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   William Foulsham, None; xuhua tan, None; Yihe Chen, None; Afsaneh Amouzegar, None; Yizhi liu, None; Sunil Chauhan, None; Reza Dana, None
  • Footnotes
    Support  NIH R01 EY20889
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2065. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      William Foulsham, xuhua tan, Yihe Chen, Afsaneh Amouzegar, Yizhi liu, Sunil Chauhan, Reza Dana; Corneal Epithelium-derived Thrombospondin-1 Regulates Dendritic Cell Maturation in Dry Eye Disease. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2065.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Thrombospondin (TSP)-1 is an important immunoregulatory factor produced by corneal epithelial cells (CECs). The purpose of this study was to investigate TSP-1-mediated regulation of dendritic cell maturation and the therapeutic efficacy of topical TSP-1 in dry eye disease (DED).

Methods : DED was induced in female C57BL/6 mice using a controlled environmental chamber for 14 days. mRNA and protein expression of TSP-1 in CECs was quantified by real-time PCR and flow cytometry at day 14. Activated bone marrow-derived dendritic cells (DCs) were co-cultured with CECs from either naïve or DED mice, and the frequencies of MHC-IIhi and CD86+ DCs were evaluated with flow cytometry. These experiments were repeated in the presence of recombinant TSP-1, and also anti-TSP-1 antibody. Finally, DED mice were treated topically with either recombinant TSP-1 or serum albumin. Infiltration and maturation of corneal dendritic cells, expression of inflammatory cytokines, and DED severity were investigated.

Results : mRNA expression of TSP-1 was upregulated in CECs from DED mice compared to naïve mice (p<0.001). Although there was no significant difference in the frequencies of TSP-1-expressing CECs between naïve and DED mice, the mean fluorescence intensity of TSP-1 in CECs from DED mice was significantly increased (p=0.016). The frequencies of MHC-IIhi and CD86+ DCs in the presence of DED corneal epithelium were lower than in the presence of naïve corneal epithelium, although the value for CD86+ DCs failed to reach statistical significance (p=0.015 and p=0.117, respectively). Addition of recombinant TSP-1 to the co-culture system resulted in a significant decrease in frequencies of MHC-IIhi and CD86+ DCs (p=0.013 and p=0.008, respectively), while addition of TSP-1 antibody abrogated this suppressive effect (p=0.030 and p=0.015, respectively). Topical administration of recombinant TSP-1 was found to significantly inhibit the maturation and infiltration of corneal DCs, suppress inflammatory cytokine expression at the ocular surface, and reduce the corneal fluorescein staining score in DED mice (p<0.05).

Conclusions : Our results demonstrate that CEC-derived TSP-1 inhibits DC maturation, and that topical administration of recombinant TSP-1 suppresses ocular inflammation and reduces disease severity in DED mice.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×